Physician profile
Daniel Rachal
NPI 1689135048
$6,428.15
in general payments reported to CMS, 2019-2025
33 companies · $2,541 in 2025
The $2,541 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.17 · 2022: $25.10 · 2023: $1,507 · 2024: $2,326 · 2025: $2,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,092.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,092.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $791.71 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $418.79 | 2023-2025 | |
| Novo Nordisk INC | $391.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $346.41 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.74 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $296.64 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $238.48 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.02 | 2023-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $166.38 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $165.69 | 2023-2024 | Linzess |
| Shield Therapeutics INC | $164.18 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $91.68 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $73.68 | 2021-2023 | Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.16 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $66.15 | 2023-2025 | Prolia, Evenity, Otezla |
| Exact Sciences Corporation | $48.89 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $42.27 | 2023-2025 | Inspire |
| Lundbeck LLC | $41.11 | 2025 | Rexulti |
| Corcept Therapeutics | $39.89 | 2025 | Korlym |
| Insulet Corporation | $29.84 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $29.07 | 2023-2024 | Livalo |
| Ironshore Pharmaceuticals INC. | $24.76 | 2024 | |
| Vanda Pharmaceuticals INC. | $22.60 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.72 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $20.63 | 2023 | |
| Biogen, INC. | $19.53 | 2024 | Skyclarys |
| Xeris Pharmaceuticals, INC. | $18.80 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.28 | 2025 | Veozah |
| Genzyme Corporation | $17.20 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.54 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $12.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rachal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.